🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prospective Longitudinal Observational Research in Atopic Dermatitis

Recruitingn/aAges 1 Year - 85 YearsAllUniversity of Zurich
NCT04240522 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life. In 30 - 60% of children, inflammation spreads onto other body surfaces such as the gastrointestinal tract, the respiratory tract, and the conjunctives within a few years. This sequence is called atopic march. Atopic dermatitis and associated atopic diseases are more frequent in families, suggesting a genetic predisposition. However, the underlying factors such as genetic phenotype, environmental factors, or life style which cause or worsen an existing allergic disease are not understood yet. Affected people suffer from recurrent flares that result in significantly impaired quality. This study will collect clinical and laboratory data to elucidate immunotolerance and preventiv stategies with the aim to develop new

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 0 - 85 years * Diagnosis of AD and/or another disease of the atopic group (i.e. allergic rhinitis, allergic asthma, food allergy) * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated The inclusion criteria for healthy controls in this study are as follows: * Age 0 - 85 years * No diagnosis or history of allergic disease * The inclusion of patients in this study is independent from the current therapy. During the study all patients will be kept on a therapy that is medically indicated Written consent will be obtained after detailed information of the study was given to the participant. Exclusion Criteria \- Unable to give consent or refusal to participate in the study
💊

What it tests

  • Not listed
📍

Where

1 site
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich
Zurich, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy